RemeGen Co (SHSE:688331) Short-Term Debt: ¥1,426 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688331 RemeGen Co Ltd SHSE:688331
44 GF Score
Price ¥113.05
GF Value ¥276.84
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Short-Term Debt?

RemeGen Co SHSE:688331 +1.44% 44 Short-Term Debt is ¥1,426 Mil as of Dec. 2025. GuruFocus rates SHSE:688331 with a GF Score™ of 44/100 and a GF Value™ of ¥276.84 (Modestly Undervalued). The stock has 6 warning signs investors should review.

RemeGen Co's Short-Term Debt for the quarter that ended in Dec. 2025 was ¥1,426 Mil.

RemeGen Co's quarterly Short-Term Debt declined from Jun. 2025 (¥1,788 Mil) to Sep. 2025 (¥1,071 Mil) but then increased from Sep. 2025 (¥1,071 Mil) to Dec. 2025 (¥1,426 Mil).

RemeGen Co's annual Short-Term Debt increased from Dec. 2023 (¥286 Mil) to Dec. 2024 (¥1,370 Mil) and increased from Dec. 2024 (¥1,370 Mil) to Dec. 2025 (¥1,426 Mil).

RemeGen Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

RemeGen Co Short-Term Debt Related Terms

RemeGen Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Short-Term Debt Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 286.35 1,370.24 1,426.41

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,026.77 1,370.24 1,787.58 1,071.41 1,426.41
SHSE:688331
44GF Score
RemeGen Co Ltd SHSE:688331
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥1,426 Mil mean?
RemeGen Co (SHSE:688331) has a Short-Term Debt of ¥1,426 Mil as of Dec. 2025.
Is RemeGen Co's Short-Term Debt too high?
RemeGen Co's current Short-Term Debt is ¥1,426 Mil. Overall, RemeGen Co has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Short-Term Debt compare to VRTX and REGN?
RemeGen Co's Short-Term Debt of ¥1,426 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. RemeGen Co's current Short-Term Debt is ¥1,426 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (SHSE:688331) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥276.84, compared to a current price of ¥113.05 — trading 59.2% below its estimated fair value. The current Short-Term Debt is ¥1,426 Mil. RemeGen Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For RemeGen Co (SHSE:688331), the current Short-Term Debt is ¥1,426 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (SHSE:688331) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of ¥113.05 is trading 59.2% below its estimated GF Value™ of ¥276.84. GuruFocus considers RemeGen Co to be Modestly Undervalued.

Key valuation signals for SHSE:688331:

  • Short-Term Debt: ¥1,426 Mil
  • GF Value™: ¥276.84 vs. price of ¥113.05 (59.2% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
44GF Score

Get the complete analysis for SHSE:688331

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥113.05
Price
¥276.84
GF Value